^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Hansoh Xinfu (flumatinib) (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed BCR::ABL1-Positive Acute Lymphoblastic Leukemia in Adults: Updated Results from RJ-ALL2020.2A Trial
Published date:
11/02/2023
Excerpt:
There was a survival superiority in pts who achieved MRD flow negativity (PFS: p=0.091, OS: p=0.005) or CMR (PFS: p=0.055; OS: p=0.033) at 3 months….This prospective study further confirmed the efficacy and safety of the promising second-generation TKI flumatinib combined with chemotherapy in newly-diagnosed Chinese adult pts with BCR::ABL1+ ALL.
DOI:
https://doi.org/10.1182/blood-2023-180326
Source:
Title:
A PHASE II STUDY OF FLUMATINIB WITH CHEMOTHERAPY FOR NEWLY DIAGNOSED PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS: UPDATED RESULTS FROM RJ-ALL2020.2A TRIAL
Published date:
05/11/2023
Excerpt:
With a median follow-up time of 14 months (range, 2-23), the 1-year PFS and OS rates were 86.1% and 92.5%...The combination of the novel second-generation TKI flumatinib and chemotherapy is quite effective and safe in newly-diagnosed Chinese adult pts with Ph/BCR-ABL1+ ALL...
Secondary therapy:
Chemotherapy
